Interestingly, in breast cancers, the rationale for anti-PDIA17 therapy was offered for oestrogen receptor (ER)-positive breast cancers (e.g., MCF-7) but not ER-negative breast cancers (e.g., MDA-MB-231) [43–45]. Here, AGR2 is linked to breast carcinoma.